American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

CDC data highlights surge in obesity rates, driving demand for weight loss drugs

by admin September 13, 2024
September 13, 2024
CDC data highlights surge in obesity rates, driving demand for weight loss drugs

Recent data from the Centers for Disease Control and Prevention (CDC) underscores a dramatic shift in obesity trends across the US over the past decade.

The 2023 figures highlight a persistent and widespread obesity crisis, bolstering the market for weight loss drugs, where Eli Lilly and Novo Nordisk are currently the leading players.

Key findings from the CDC data

The CDC’s latest report reveals that every US state now has at least 20% of its adult population classified as obese.

Notably, 23 states have an obesity prevalence exceeding 35%, indicating that one in three adults in these regions could benefit from weight loss treatments.

Obesity is often linked to factors beyond diet, and the CDC emphasizes the urgent need for advanced treatment options.

According to Karen Hacker of the CDC, this data underscores the critical demand for effective obesity prevention and treatment strategies.

In response to the growing need, Novo Nordisk and Eli Lilly have emerged as leaders in the weight loss drug market.

Novo Nordisk’s Wegovy, a GLP-1 receptor agonist, and Eli Lilly’s Zepbound have been particularly successful.

Both companies have seen substantial revenue increases over the past year due to the high demand for their weight loss solutions.

Novo Nordisk vs. Eli Lilly

Novo Nordisk is expanding its portfolio with amycretin, a new drug that combines two peptide hormones in a single molecule.

This innovative approach aims to enhance appetite regulation and hunger control, offering a potential alternative to Wegovy.

In response to the high demand and supply constraints, Eli Lilly is investing $1.8 billion to boost its production capabilities for weight loss, Alzheimer’s, and diabetes medications.

The company is focusing on expanding its Kinsale, Ireland facility, with an additional $800 million investment to increase its manufacturing capacity.

UBS now expects the weight loss drug market to grow at a compound annualized rate of 33% and hit $150 billion in sales by 2029 – up from the firm’s earlier forecast of about $125 billion. 

The company has also achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. 

Novo Nordisk has also got approval for its weight-loss drug from China.

Both Novo Nordisk and Eli Lilly are well-positioned to capitalize on the ongoing obesity trend.

Despite current short-term supply issues potentially impacting stock performance, the long-term outlook for these companies remains strong.

Their advancements and expansions in the weight loss sector suggest promising medium-term investment opportunities.

The post CDC data highlights surge in obesity rates, driving demand for weight loss drugs appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Are Lloyds Bank, NatWest, and Barclays at risk from Revolut?
next post
Is Rivian truly ‘one or two programs away from bankruptcy’?

Related Posts

AstraZeneca pauses £200mn Cambridge investment amid UK pharma...

September 13, 2025

3M Q3 earnings report today: Will it boost...

October 22, 2024

Lucid Group stock forecast ahead of earnings: buy,...

May 6, 2025

Inside Robinhood’s ‘apocalypse’ team: Vlad Tenev reveals his...

August 15, 2025

Weekly wrap: A US shutdown; a UK terror...

October 5, 2025

Trump admin bars Harvard from enrolling international students

May 23, 2025

JPMorgan projects another 15-20% surge in Asian tech...

June 24, 2025

Temple University reviewing reports of potential match-fixing of...

March 9, 2024

Nippon Steel’s plan to buy US Steel blocked...

January 3, 2025

Snap stock price at critical juncture: will it...

April 28, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Europe bulletin: Manchester synagogue attack aftermath, stocks close higher

      October 5, 2025
    • Evening digest: Trump sets deadline for Hamas, Canada’s slowdown, BTC rebounds

      October 5, 2025
    • Iran executes six people for alleged links to Israel, state media reports

      October 5, 2025
    • US digest: Trump’s Hamas ultimatum, government shutdown stalemate continues

      October 5, 2025
    • Japanese stocks may extend record run as Takaichi win revives ‘Abenomics’

      October 5, 2025

    Categories

    • Business (4,181)
    • Investing (2,955)
    • Latest News (2,080)
    • Politics (1,536)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved